SRPT
$16.84
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases...
Recent News
KROS: Is the Discount Book Value a Value Trap?
Keros posts a 2025 revenue surge from Takeda licensing, but no product sales and volatile drivers leave investors weighing a discounted valuation against execution risk.
KROS Pipeline Catalysts: DMD Phase II and ALS Plans for 2026
Keros lines up 2026 catalysts with rinvatercept at the core, including a Q2 DMD phase II start and ALS regulatory plans as execution shifts into focus.
KROS Stock: What to Know About Rinvatercept in DMD
Keros advances rinvatercept in DMD with orphan status, fresh phase I data, and a planned Q2 2026 phase II start driving its near-term execution story.
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy
Sarepta has begun evaluating a regimen meant to lower the risk of liver damage in Elevidys recipients. Elsewhere, Inovio laid off staff and a Bayer kidney drug notched another trial victory.